[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381602-105":59,"doc-detail-381602-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-value-of-her2-low-status-in-breast-cancer-a-systematic-review-and-meta-analysis","Prognostic value of HER2-low status in breast cancer - a systematic review and meta-analysis","","Human epidermal growth factor receptor 2 (HER2)-low expression has emerged as a new therapeutic target in breast cancer, yet its independent prognostic role remains uncertain. This systematic review and meta-analysis compares survival outcomes for patients with HER2-low versus HER2-zero disease across metastatic and early settings, estimating pooled hazard ratios and odds ratios with 95% confidence intervals. Random-effects analyses evaluate progression-free survival, overall survival, disease-free survival, and pathological complete response, with subgroup analyses by hormone receptor status.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-value-of-her2-low-status-in-breast-cancer-a-systematic-review-and-meta-analysis/381602/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-value-of-her2-low-status-in-breast-cancer-a-systematic-review-and-meta-analysis/381602.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about HER2-low status?","Question",{"text":112,"@type":113},"It evaluates whether HER2-low status has an independent impact on prognosis compared with HER2-zero status in breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes compared between HER2-low and HER2-zero groups?",{"text":117,"@type":113},"The study systematically identified trials comparing survival outcomes, then used random-effects models to pool hazard ratios and odds ratios with 95% confidence intervals.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings in early and metastatic settings?",{"text":121,"@type":113},"In the early setting, HER2-low status was associated with improved disease-free survival and overall survival, while pathological complete response rates were lower. In the metastatic setting, overall survival was better for HER2-low overall, and no significant progression-free survival differences were detected.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},381602,1790728417,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","ORIGINAL RESEARCH  \nPrognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis  \nC. Molinelli1 , 2, F. Jacobs1, 3, E. Agostinetto1, G. Nader-Marta1, M. Ceppi4, M. Bruzzone4, E. Blondeaux4, F. Schettini5, 6, 7,  \nA. Prat5, 7, 8, G. Viale9, L. Del Mastro2, 10, M. Lambertini2, 10 & E. de Azambuja1, 11 􀀁  \n1Academic Trials Promoting Team, Institut Jules Bordet and l’Université Libre de Bruxelles (ULB), Brussels, Belgium; 2Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa; 3Department of Biomedical Sciences, Humanitas University, Milan; 4Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 5Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; 6Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona; 7Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona; 8Reveal Genomics, Barcelona, Spain; 9Department of Pathology, IEO European Institute of Oncology IRCCS, Milan; 10Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 11Medical Oncology Department, Institut Jules Bordet and l’Université Libre de Bruxelles (ULB), Brussels, Belgium  \nAvailable online 4 July 2023  \nBackground: Human epidermal growth factor receptor 2 (HER2)-low expression in breast cancer has been recently identified as a new therapeutic target. However, it is unclear if HER2-low status has an independent impact on prognosis.  \nMaterials and methods: A systematic literature research was carried out to identify studies comparing survival outcomes of patients affected by HER2-low versus HER2-zero breast cancer. Using random-effects models, pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for progression-free survival (PFS) and overall survival (OS) in the metastatic setting as well as disease-free survival (DFS), OS and pathological complete response (pCR) in the early setting. Subgroup analyses by hormone receptor (HoR) status were carried out. The study protocol is registered on PROSPERO (n.CRD42023390777) .  \nResults: Among 1916 identified records, 42 studies including 1 797 175 patients were eligible. In the early setting, HER2-low status was associated with significant improved DFS (HR 0 .86, 95% CI 0 .79-0.92, P \u003C 0.001) and OS (HR 0.90, 95% CI 0 .85-0.95, P \u003C 0.001) when compared to HER2-zero status. Improved OS was observed for both HoRpositive and HoR-negative HER2-low populations, while DFS improvement was observed only in the HoR-positive subgroup. HER2-low status was significantly associated with a lower rate of pCR as compared to HER2-zero status both in the overall population (OR 0 .74, 95% CI 0 .62-0.88, P ¼ 0.001) and in the HoR-positive subgroup (OR 0 .77, 95% CI 0 .65-0.90, P ¼ 0.001) . In the metastatic setting, patients with HER2-low breast cancers showed better OS when compared with those with HER2-zero tumours in the overall population (HR 0 .94, 95% CI 0 .89-0.98, P ¼ 0.008), regardless of HoR status. No significant PFS differences were found.  \nConclusions: Compared with HER2-zero status, HER2-low status appears to be associated with a slightly increased OS both in the advanced and early settings, regardless of HoR expression. In the early setting, HER2-low tumours seem tobe associated to lower pCR rates, especially if HoR-positive.  \nKey words: breast cancer, HER2-low, HER2-zero  \n*Correspondence to: Dr Evandro de Azambuja, Academic Trials Promoting Team, Institut Jules Bordet, Rue Meylemeersch, 90 (Rez Haut Nord)dB-1070 Anderlecht, Brussels, Belgium. Tel: þ32 (0) 2 541 72 44  \nE-mail: [evandro.deazambuja@hubruxelles.be](evandro.deazambuja@hubruxelles.be) (E. de Azambuja).  \nTwitter handle: @E_de_Azambuja, @ChiaraMolinelli, @FlaviaJacobs_,@ElisaAgostinett, @Nader_Guilherme, @BlondeauxEva, @Frances","cbCairHVRNsBhF9s","https://ap.wps.com/l/cbCairHVRNsBhF9s","pdf",1197902,11,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction\n# Key words","[{\"question\":\"What question does the study address about HER2-low status?\",\"answer\":\"It evaluates whether HER2-low status has an independent impact on prognosis compared with HER2-zero status in breast cancer.\"},{\"question\":\"How were outcomes compared between HER2-low and HER2-zero groups?\",\"answer\":\"The study systematically identified trials comparing survival outcomes, then used random-effects models to pool hazard ratios and odds ratios with 95% confidence intervals.\"},{\"question\":\"What were the main findings in early and metastatic settings?\",\"answer\":\"In the early setting, HER2-low status was associated with improved disease-free survival and overall survival, while pathological complete response rates were lower. In the metastatic setting, overall survival was better for HER2-low overall, and no significant progression-free survival differences were detected.\"}]","Prognostic value of HER2-low status in breast cancer - a systematic review and meta-analysis | PDF",1790246135,28]